Danaher Corporation $DHR Shares Sold by Swedbank AB

Key Points

• Swedbank AB has reduced its stake in Danaher Corporation by 2.2%, now holding 985,681 shares valued at approximately $194.71 million.
• Danaher reported a quarterly earnings per share of $1.80, exceeding analyst expectations, with a revenue of $5.94 billion for the last quarter.
• The company recently announced a quarterly dividend of $0.32 per share, set to be paid on October 31st, with a current dividend yield of 0.7%.

Swedbank AB lowered its stake in Danaher Corporation (NYSE:DHR - Free Report) by 2.2% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 985,681 shares of the conglomerate's stock after selling 22,657 shares during the quarter. Swedbank AB owned about 0.14% of Danaher worth $194,711,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. MGO One Seven LLC grew its holdings in Danaher by 485.7% during the 1st quarter. MGO One Seven LLC now owns 25,098 shares of the conglomerate's stock valued at $5,145,000 after buying an additional 20,813 shares in the last quarter. UniSuper Management Pty Ltd grew its holdings in Danaher by 1.6% during the 1st quarter. UniSuper Management Pty Ltd now owns 170,505 shares of the conglomerate's stock valued at $34,954,000 after buying an additional 2,667 shares in the last quarter. Asahi Life Asset Management CO. LTD. purchased a new position in Danaher during the 1st quarter valued at approximately $539,000. Horizon Financial Services LLC lifted its stake in shares of Danaher by 20,400.0% in the 1st quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate's stock valued at $1,681,000 after purchasing an additional 8,160 shares during the last quarter. Finally, Focus Partners Wealth lifted its stake in shares of Danaher by 10.7% in the 1st quarter. Focus Partners Wealth now owns 196,682 shares of the conglomerate's stock valued at $40,328,000 after purchasing an additional 19,086 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company's stock.

Insider Activity at Danaher

In other Danaher news, Director Teri List sold 2,778 shares of the stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the transaction, the director owned 20,751 shares of the company's stock, valued at $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 11.10% of the stock is owned by insiders.

Danaher Stock Performance

Shares of DHR traded down $2.33 during mid-day trading on Monday, reaching $190.96. The company had a trading volume of 979,218 shares, compared to its average volume of 4,133,804. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $279.90. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $136.74 billion, a P/E ratio of 40.63, a PEG ratio of 2.70 and a beta of 0.75. The stock has a 50 day moving average of $200.17 and a two-hundred day moving average of $198.18.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. The company had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.Danaher's quarterly revenue was up 3.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, analysts expect that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be issued a $0.32 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a yield of 0.7%. Danaher's dividend payout ratio is presently 27.23%.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Evercore ISI decreased their target price on Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. Wells Fargo & Company cut their price target on Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a report on Wednesday, July 23rd. Wall Street Zen upgraded Danaher from a "hold" rating to a "buy" rating in a report on Friday, June 27th. Royal Bank Of Canada set a $241.00 price target on Danaher in a research note on Tuesday, September 2nd. Finally, UBS Group lowered their price target on Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a report on Wednesday, July 23rd. Seventeen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $246.35.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.